<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723121</url>
  </required_header>
  <id_info>
    <org_study_id>AE20121</org_study_id>
    <nct_id>NCT04723121</nct_id>
  </id_info>
  <brief_title>Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers</brief_title>
  <official_title>Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravesical BCG is the mainstay adjuvant management of high risk NMIBC. Adequacy of immune&#xD;
      system stimulation is the determinant factor for patient response to BCG. Immunological&#xD;
      markers for BCG-response could be helpful for urologists especially in the era of BCG&#xD;
      shortage.&#xD;
&#xD;
      Objectives: To assess the predictive performance of different immunological markers on&#xD;
      BCG-response in high risk NMIBC BCG-naïve patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Intravesical BCG is the mainstay adjuvant management of high risk NMIBC. Adequacy&#xD;
      of immune system stimulation is the determinant factor for patient response to BCG.&#xD;
      Immunological markers for BCG-response could be helpful for urologists especially in the era&#xD;
      of BCG shortage.&#xD;
&#xD;
      Objectives: To assess the predictive performance of different immunological markers on&#xD;
      BCG-response in high risk NMIBC BCG-naïve patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2013</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial BCG complete response</measure>
    <time_frame>3 months</time_frame>
    <description>free cystoscopy/negative cytology at 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrence is defined as development of new tumor/positive cytology in patients with ICR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression</measure>
    <time_frame>1 year</time_frame>
    <description>persistent/recurrent tumor during or after treatment with increasing tumor grade or upstaging to muscle invasion after initial complete response</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>High risk NMIBC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with primary or recurrent NMIBC for whom primary TURBT was done and intravesical BCG was administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine ELISA for immunological markers (IL-2 and IL-10)</intervention_name>
    <description>IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively</description>
    <arm_group_label>High risk NMIBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis</intervention_name>
    <description>blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control</description>
    <arm_group_label>High risk NMIBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with primary or recurrent NMIBC for whom primary TURBT was done.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with previous BCG instillation,&#xD;
&#xD;
          2. benign pathology&#xD;
&#xD;
          3. Variant histology&#xD;
&#xD;
          4. Non urothelial carcinoma,&#xD;
&#xD;
          5. concommitent upper tract urothelial tumors, detrusor muscle invasion&#xD;
&#xD;
          6. low or intermediate risk NMIBC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amr A Elsawy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urology and Nephrology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <state>DK</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Amr Abdel-Lateif El-Sawy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>Bacillus Calmette-Guérin response</keyword>
  <keyword>Prediction</keyword>
  <keyword>Urinary cytokines</keyword>
  <keyword>T cells</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

